Indeed, exposure to DCA, or knock-down of PDK3 with siRNA, has been shown to potentiate elesclomol’s induction of oxidative stress in melanoma cell lines, and concurrent treatment with DCA amplified the growth retardation of a human melanoma achieved with elesclomol in nude mice (41). The gene discussed is PDK3; the disease is melanoma.